Cadila Healthcare settles patent issue with Supernus Pharmaceuticals

08 Mar 2017 Evaluate

Cadila Healthcare, along with subsidiary Zydus Pharmaceuticals (USA) Inc, has finalized an agreement with Supernus Pharmaceuticals Inc to settle all outstanding patent litigation related to Trokendi XR (topiramate) extended-release capsules.

Under the terms of the pact, Supernus grants a license to market Zydus' generic version of Trokendi XR (topiramate) extended-release capsules beginning on January 1, 2023, or earlier, under certain circumstances. The drug is used for treatment of certain types of seizures.

Cadila Healthcare is part of the Zydus Cadila Group. The company operates in areas of active pharmaceutical ingredients (API) to formulations, and animal health products to cosmeceuticals. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in over 50 countries around the world.

Zydus Lifesciences Share Price

914.75 0.85 (0.09%)
17-Dec-2025 10:57 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1772.55
Dr. Reddys Lab 1269.10
Cipla 1491.50
Zydus Lifesciences 914.75
Lupin 2103.30
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×